A commentary on “Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials” (Int J Surg. 2024 May 3.)

aDepartment of Cardiology, The Second Hospital of Dalian Medical University, Dalian 116021, Liaoning, China bDepartment of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian 116000, China cDepartment of Encephalology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450046, Henan, China Guolin Zhang, MD, Zhen Wang These authors have contributed equally to this work. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: [email protected] (H. Yu). *Corresponding author. Address: [email protected] (X. Liu). This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0/